Lilly’s Retevmo receives FDA approval to treat solid tumours
Retevmo (selpercatinib, 40 mg & 80 mg capsules) is indicated to treat locally advanced or metastatic solid tumours in adult patients with a rearranged during transfection (RET) gene
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of about $750m.